Page 1

GENFIT TOWARDS BETTER MEDICINE PRESS RELEASE • • • GENFIT Provides Pipeline Update and Launch of New Clinical Programs R & D effort refocused on two therapeutic areas with significant unmet medical needs : ACLF and cholestatic diseases GENFIT well positioned to leverage its experience from discovery to late development stages in these severe liver diseases These two new franchises will focus on developing NTZ , elafibranor and GFT1575 drug- candidates Three new clinical trials to be launched in 4Q21 in ACLF , PSC and PBC , with data expected in 2022 Lille , France ; Cambridge , MA ; May 11 , 2021 - GENFIT ( Nasdaq and Euronext : GNFT ) , a late - stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases , today announced a refocus of its R & D on acute on chronic liver failure ( ACLF ) and cholestatic diseases . ACLF Acute on Chronic Liver Failure ( ACLF ) , a syndrome in patients with chronic liver disease and cirrhosis characterized by acute hepatic decompensation resulting in liver failure and / or one or more extrahepatic organ failures , is associated with increased risk for short - term mortality . There are no approved drugs to treat patients and therefore a need exists for a therapy that helps them to survive without transplantation . GENFIT is launching a clinical program with nitazoxanide ( NTZ ) in this disease . A Phase 1 study to evaluate pharmacokinetics and pharmacodynamics in patients with varying degrees of hepatic impairment is expected to start in 4Q21 with clinical data expected end of 2022. GENFIT will also explore the potential of proprietary compounds elafibranor and GFT1575 in ACLF . Cholestatic diseases Chronic cholestatic diseases are characterized by defective bile acid transport from the liver to the intestine , which is caused by primary damage to the biliary epithelium in most cases¹ . GENFIT is already present in this therapeutic area with ELATIVE ™ , its Phase 3 clinical trial evaluating the potential of its lead drug - candidate elafibranor in Primary Biliary Cholangitis ( PBC ) . 1 Poupon R. et al . J of Hepatol , Volume 32 , SUPPLEMENT 1 , 129-140 , January 01 , 2000 GENFIT | 885 Avenue Eugène Avinée , 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1